BEIJING, China — October 13, 2026 — A research team in China has announced a breakthrough in livestock biosecurity, developing a novel messenger RNA (mRNA) vaccine targeting the EG95 antigen of Echinococcus granulosus. Published in veterinary immunology literature, trial data confirms that the mRNA formulation achieved significantly higher antibody titers, longer-lasting cell-mediated immunity, and superior protective efficacy in lambs compared to traditional recombinant protein vaccines.
Addressing Zoonotic Cystic Echinococcosis
Cystic echinococcosis (hydatid disease) remains a severe parasitic zoonosis affecting ruminants and humans across pastoral regions, causing substantial livestock liver/lung condemnation losses and public health burdens.
-
Enhanced Antigenic Expression: The synthetic mRNA platform delivers optimized genetic instructions directly to host immune cells, bypassing protein degradation bottlenecks common in conventional adjuvant formulations.
-
Extended Protection Duration: In comparative field challenge trials, lambs immunized with the mRNA-EG95 candidate demonstrated complete suppression of oncosphere establishment for over 12 months post-boost.
-
Global One Health Relevance: The success of livestock-directed mRNA vaccines opens a scalable, rapid-manufacturing paradigm for controlling neglected parasitic zoonoses without relying on continuous antiparasitic chemical dosing.
